Xenon Pharmaceuticals Inc   (XENE)
Other Ticker:  
Price: $46.8400 $-0.36 -0.763%
Day's High: $50.99 Week Perf: -4.66 %
Day's Low: $ 46.70 30 Day Perf: 3.58 %
Volume (M): 721 52 Wk High: $ 50.99
Volume (M$): $ 33,786 52 Wk Avg: $38.85
Open: $49.70 52 Wk Low: $27.99

 Market Capitalization (Millions $) 3,092
 Shares Outstanding (Millions) 66
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -175
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 7

Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc is a Canadian biopharmaceutical company that specializes in the discovery and development of novel therapies for neurological disorders. The company focuses on targeting ion channels, which are proteins involved in electrical signaling within the nervous system. Xenon utilizes a proprietary drug discovery platform called Extreme Genetics' to identify rare mutations in genes that are associated with particular diseases. This approach allows the company to develop precision medicines tailored to specific patient populations. Xenon is engaged in various clinical programs targeting conditions such as epilepsy, migraine, and neurologic channelopathies. As of now, Xenon's pipeline includes both early-stage investigational drugs and those in advanced stages of clinical development.

   Company Address: 200-3650 Gilmore Way Burnaby 0 BC
   Company Phone Number: 484-3300   Stock Exchange / Ticker: NASDAQ XENE


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Xenon Pharmaceuticals Reports Strong Financial Results and Advances in Epilepsy Program

Published Thu, Feb 29 2024 9:01 PM UTC

Xenon Pharmaceuticals Achieves Solid Financial Performance as Its Epilepsy Program AdvancesXenon Pharmaceuticals, a leading biopharmaceutical company, recently released its financial results for the fourth quarter and full year of 2023. The company reported strong growth, driven by its innovative epilepsy program and close collaboration with corporate clients. Additionally, ...

Clinical Study

Xenon Pharmaceuticals to Unveil Exciting Neurology Breakthroughs at AES 2023 Conference

Published Sat, Dec 2 2023 5:01 PM UTC

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
VANCOUVER, British Columbia, Dec. 02, 2023 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, has recently announced that it will be providing updates on its neurology programs at the Annual Meetin...

Financing Agreement

Xenon Pharmaceuticals Empowers Neurology Research with $225 Million Public Offering

Published Wed, Nov 29 2023 9:03 PM UTC

On November 29, 2023, Xenon Pharmaceuticals Inc., a leading biopharmaceutical company focusing on neurology, made a significant announcement regarding its plans for a new public offering. The company has commenced an underwritten public offering, aiming to raise $225.0 million through the issuance of common shares. Additionally, Xenon provides an option to certain ...

Clinical Study

Xenon Pharmaceuticals Announces Positive Results from X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)

Published Mon, Nov 27 2023 12:00 PM UTC

Xenon Pharmaceuticals, a leading clinical-stage biopharmaceutical company, announced the awaited topline results from their Phase 2 proof-of-concept X-NOVA clinical trial, which evaluated the efficacy and safety of XEN1101 in patients diagnosed with Major Depressive Disorder (MDD). The groundbreaking trial results were shared via a conference call held today at 8:30 am ...

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc. Reports Stable Revenue, Signaling Consistency in Recent Fiscal Year

In what seems to be a challenging fiscal period, Xenon Pharmaceuticals Inc has reported a decline in earnings and a significant drop in stock value in recent months. The company's financial results portray an alarming downward trend, raising concerns among analysts and investors alike. This article aims to shed light on the financial performance of Xenon Pharmaceuticals Inc, examining its recent fiscal period results and the context of its declining stock value.
Earnings Performance:
Xenon Pharmaceuticals Inc experienced a larger shortfall per share of $-0.73 in the most recent fiscal period, in comparison to $-0.57 reported a year ago. This indicates a deterioration in earnings, further exacerbated by a growth in shortfall from the previous financial reporting period, which stood at $-0.72 per share.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com